BioCentury | Sep 30, 2020
Product Development

Sept. 29 Quick Takes: Ironwood reduces headcount following Phase III miss; plus Sandoz, Catalyst, Myovant, Orphazyme, Synklino, WHO, BridgeBio, Kurma, Junshi, Arcutis, Genfit-LabCorp and GSK

...By BC Staff Ironwood to downsize after Phase III GERD failureIronwood Pharmaceuticals Inc. (NASDAQ:IRWD) said it...
BioCentury | May 16, 2020
Management Tracks

Management Tracks: Evox, Phoenix Tissue Repair, Artax, Nucleix, IsoPlexis, Centogene, Immunicum, CohBar and CorMedix

...Single-cell analytics company IsoPlexis Corp. hired John Strahley as CFO. He was managing director of Ironwood...
BioCentury | Nov 21, 2019
Company News

Alnylam unveils pricing strategy for second FDA-approved RNAi drug

...6,000 patients with active disease in the U.S. and Europe. In August, Alnylam partnered with Ironwood Pharmaceuticals Inc....
...other healthcare practitioners within its network for constipation and irritable bowel syndrome drug Linzess linaclotide. Ironwood...
BioCentury | Nov 18, 2019
Clinical News

Heart failure notches another win as Merck, Bayer's sGC stimulator meets in Phase III

...the oral sGC stimulator missed the primary endpoint in the Phase II CAPACITY trial (see "Ironwood...
BioCentury | Oct 30, 2019
Company News

Oct. 30 Company Quick Takes: Clinical hold for Zolgensma; plus Biogen-Alkermes, Roche’s satralizumab, Pear-Ironwood

...expected in 2020. Pear, Ironwood in digital deal for GI indications Pear Therapeutics Inc. and Ironwood Pharmaceuticals Inc....
...market (see “Pear Gearing up to Sell Products Solo” ). BioCentury Staff IW-3718 Roche Alkermes plc Biogen Inc. Novartis AG Pear Therapeutics Inc. Ironwood Pharmaceuticals Inc. MD-7426...
BioCentury | Oct 30, 2019
Clinical News

Ironwood spinout sees path forward for platform despite lead program miss

...of its most advanced candidate sent Cyclerion tumbling just months after the company’s split from Ironwood...
...spun out of Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) in April with a pipeline of candidates targeting sGC (see “Ironwood...
BioCentury | Sep 20, 2019
Company News

Sept. 20 Company Quick Takes: Three Japanese approvals, plus AZ-Ironwood, Boehringer-Inflammasome, China Biologics and a Sino-Russian JV

...Ironwood's rights to Linzess in China AstraZeneca plc (LSE:AZN; NYSE:AZN) amended its 2012 deal with Ironwood Pharmaceuticals Inc....
...Linzess linaclotide in Greater China ahead of the drug's launch this half to treat constipation. Ironwood...
...Pharmaceutical Co. Ltd. Astellas Pharma Inc. FibroGen Inc. Takeda Pharmaceutical Co. Ltd. H. Lundbeck A/S China Biologic Products Holdings Inc. AstraZeneca plc Ironwood Pharmaceuticals Inc. Shanghai...
BioCentury | Aug 10, 2019
Financial News

Aug. 9 Financial Quick Takes: Ironwood, Clovis, MeiraGTx, Dynavax, Biocytogen and more

...Ironwood, Clovis price note deals Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) raised $350 million in a convertible notes offering, including...
...$175 million in 1.5% notes maturing June 2026. Both components were upsized from $165 million. Ironwood...
...delivery. Val Kennedy, Associate Editor, and Hongjiang Li, Staff Writer Beijing Biocytogen Co. Ltd. Clovis Oncology Inc. Dynavax Technologies Corp. Ironwood Pharmaceuticals Inc. Kangpu...
BioCentury | Jul 26, 2019
Company News

Management tracks: Obsidian builds out team; plus Agilvax, Selvita, NeuBase and more

...healthcare investment banking group at Baird. Brown was VP and chief intellectual property counsel at Ironwood Pharmaceuticals Inc....
BioCentury | Jun 19, 2019
Clinical News

June 19 Clinical Quick Takes: G1 jumps on breast cancer data; plus Linzess, Lokelma, Boehringer/OSE, GCAR and more

...CDK6 inhibitor at a medical meeting this year. Linzess meets in Phase IIIb for IBS-C Ironwood Pharmaceuticals Inc....
...G1T28, iv g1t28-1) zanubrutinib (BGB-3111) Allergan plc AstraZeneca plc Bayer AG BeiGene Ltd. Boehringer Ingelheim GmbH G1 Therapeutics Inc. Global Coalition for Adaptive Research Ironwood Pharmaceuticals Inc. OSE...
Items per page:
1 - 10 of 392
BioCentury | Sep 30, 2020
Product Development

Sept. 29 Quick Takes: Ironwood reduces headcount following Phase III miss; plus Sandoz, Catalyst, Myovant, Orphazyme, Synklino, WHO, BridgeBio, Kurma, Junshi, Arcutis, Genfit-LabCorp and GSK

...By BC Staff Ironwood to downsize after Phase III GERD failureIronwood Pharmaceuticals Inc. (NASDAQ:IRWD) said it...
BioCentury | May 16, 2020
Management Tracks

Management Tracks: Evox, Phoenix Tissue Repair, Artax, Nucleix, IsoPlexis, Centogene, Immunicum, CohBar and CorMedix

...Single-cell analytics company IsoPlexis Corp. hired John Strahley as CFO. He was managing director of Ironwood...
BioCentury | Nov 21, 2019
Company News

Alnylam unveils pricing strategy for second FDA-approved RNAi drug

...6,000 patients with active disease in the U.S. and Europe. In August, Alnylam partnered with Ironwood Pharmaceuticals Inc....
...other healthcare practitioners within its network for constipation and irritable bowel syndrome drug Linzess linaclotide. Ironwood...
BioCentury | Nov 18, 2019
Clinical News

Heart failure notches another win as Merck, Bayer's sGC stimulator meets in Phase III

...the oral sGC stimulator missed the primary endpoint in the Phase II CAPACITY trial (see "Ironwood...
BioCentury | Oct 30, 2019
Company News

Oct. 30 Company Quick Takes: Clinical hold for Zolgensma; plus Biogen-Alkermes, Roche’s satralizumab, Pear-Ironwood

...expected in 2020. Pear, Ironwood in digital deal for GI indications Pear Therapeutics Inc. and Ironwood Pharmaceuticals Inc....
...market (see “Pear Gearing up to Sell Products Solo” ). BioCentury Staff IW-3718 Roche Alkermes plc Biogen Inc. Novartis AG Pear Therapeutics Inc. Ironwood Pharmaceuticals Inc. MD-7426...
BioCentury | Oct 30, 2019
Clinical News

Ironwood spinout sees path forward for platform despite lead program miss

...of its most advanced candidate sent Cyclerion tumbling just months after the company’s split from Ironwood...
...spun out of Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) in April with a pipeline of candidates targeting sGC (see “Ironwood...
BioCentury | Sep 20, 2019
Company News

Sept. 20 Company Quick Takes: Three Japanese approvals, plus AZ-Ironwood, Boehringer-Inflammasome, China Biologics and a Sino-Russian JV

...Ironwood's rights to Linzess in China AstraZeneca plc (LSE:AZN; NYSE:AZN) amended its 2012 deal with Ironwood Pharmaceuticals Inc....
...Linzess linaclotide in Greater China ahead of the drug's launch this half to treat constipation. Ironwood...
...Pharmaceutical Co. Ltd. Astellas Pharma Inc. FibroGen Inc. Takeda Pharmaceutical Co. Ltd. H. Lundbeck A/S China Biologic Products Holdings Inc. AstraZeneca plc Ironwood Pharmaceuticals Inc. Shanghai...
BioCentury | Aug 10, 2019
Financial News

Aug. 9 Financial Quick Takes: Ironwood, Clovis, MeiraGTx, Dynavax, Biocytogen and more

...Ironwood, Clovis price note deals Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) raised $350 million in a convertible notes offering, including...
...$175 million in 1.5% notes maturing June 2026. Both components were upsized from $165 million. Ironwood...
...delivery. Val Kennedy, Associate Editor, and Hongjiang Li, Staff Writer Beijing Biocytogen Co. Ltd. Clovis Oncology Inc. Dynavax Technologies Corp. Ironwood Pharmaceuticals Inc. Kangpu...
BioCentury | Jul 26, 2019
Company News

Management tracks: Obsidian builds out team; plus Agilvax, Selvita, NeuBase and more

...healthcare investment banking group at Baird. Brown was VP and chief intellectual property counsel at Ironwood Pharmaceuticals Inc....
BioCentury | Jun 19, 2019
Clinical News

June 19 Clinical Quick Takes: G1 jumps on breast cancer data; plus Linzess, Lokelma, Boehringer/OSE, GCAR and more

...CDK6 inhibitor at a medical meeting this year. Linzess meets in Phase IIIb for IBS-C Ironwood Pharmaceuticals Inc....
...G1T28, iv g1t28-1) zanubrutinib (BGB-3111) Allergan plc AstraZeneca plc Bayer AG BeiGene Ltd. Boehringer Ingelheim GmbH G1 Therapeutics Inc. Global Coalition for Adaptive Research Ironwood Pharmaceuticals Inc. OSE...
Items per page:
1 - 10 of 392